Cullinan Oncology LLC (CGEM) — Cash Flow-to-Debt Ratio
Cullinan Oncology LLC (CGEM) has a Cash Flow-to-Debt Ratio of -1.25x as of March 2026, meaning its operating cash flow of $-46.05 Million could theoretically repay -1% of its total liabilities ($36.81 Million) in one year. See Cullinan Oncology LLC (CGEM) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cullinan Oncology LLC Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Cullinan Oncology LLC across 12 annual periods. For the full cash flow conversion analysis, see Cullinan Oncology LLC operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Cullinan Oncology LLC (2013–2025)
Year-by-year debt coverage analysis for Cullinan Oncology LLC. Check Cullinan Oncology LLC (CGEM) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.43x | $-175.75 Million | $39.64 Million | ▲ +3.9% |
| 2024 | -4.61x | $-145.30 Million | $31.50 Million | ▼ -4.1% |
| 2023 | -4.43x | $-134.28 Million | $30.29 Million | ▲ +8.7% |
| 2022 | -4.86x | $-126.66 Million | $26.09 Million | ▼ -32.0% |
| 2021 | -3.68x | $-43.43 Million | $11.81 Million | ▼ -77.8% |
| 2020 | -2.07x | $-29.77 Million | $14.39 Million | ▼ -1289.4% |
| 2019 | -0.15x | $-20.90 Million | $140.37 Million | ▲ +39.2% |
| 2018 | -0.25x | $-13.55 Million | $55.29 Million | ▲ +38.1% |
| 2016 | -0.40x | $-228.91K | $578.28K | ▼ -1950.7% |
| 2015 | -0.02x | $-24.03K | $1.24 Million | ▲ +75.8% |
| 2014 | -0.08x | $-91.72K | $1.15 Million | ▲ +88.6% |
| 2013 | -0.70x | $-718.41K | $1.03 Million | — |